

DAFTAR PUSTAKA

- Abrar, A., Shahzadi, S., Khurram, M. & Bushra, H.T. 2016. Sofa score and outcome: Experience at a public sector hospital ICU. *Pak Armed Forces Med J*, 66(4):510-14.
- Acharya, S.P., Pradhan, B. & Marhatta, M.N. 2007. Application of “the Sequential Organ Failure Assessment (SOFA) score” in predicting outcome in ICU patients with SIRS, *Kathmandu University Medical Journal* , 5(4):475-483.
- Afsar, I. & Sener, A.G. 2014. Is Procalcitonin a Diagnostic and/or Prognostic Marker in Sepsis? *Infectious Diseases in Clinical Practice*, 23: 3-6.
- Anam, V., Maleedhu, P., Bhaskar, M.V. & Venugopal, L. 2016. Evaluation of Serum Procalcitonin Levels and Sequential Organ Failure Assessment Score in Assessing the Severity and Outcome of Sepsis. *International Journal of Scientific Study*, 3(10).
- Anand, D., Das, S., Ray, S., Bhargava, S. & Srivastava, L.M. 2014. Interrelationship Between Procalcitonin and Organ Failure in Sepsis. *Ind J Clin Biochem*, 29(1):93-96.
- Anand, D., Das, S., Ray, S., Bhargava, S. & Srivastava, L.M. 2014. Interrelationship Between Procalcitonin and Organ Failure in Sepsis. *Ind J Clin Biochem*, 29(1):93–96.
- Andrijevic, I., Matijasevic, J., Andrijevic, L., Kovacevic, T. & Zaric, B. 2014. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. *Ann Thorac Med*, 9:162-7.
- Annam, V., Maleedhu, P., Bhaskar, M.V., Venugopal, L. 2016. Evaluation of Serum Procalcitonin Levels and Sequential Organ Failure Assessment Score in Assessing the Severity and Outcome of Sepsis *International Journal of Scientific Study*, 3(10).
- Annane, D., Bellissant, E. & Cavaillon, J.M. 2005. Septic Shock. *Lancet*, 365(9453):63-78.
- Arifin, Zainal. 2011 . *Penelitian Pendidikan:Metode dan Paradigma Baru*. Bandung: PT.Remaja Rosdakarya.
- Arikunto, Suharsimi, 2010. *Prosedur Penelitian Suatu Pendekatan Praktek*. Jakarta: Penerbit Rineka Cipta.
- Assicot, M., Gendrel, D., Carsin, H., Raymond, J., Guilbaud, J. & Bohuon, C. 1993. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet*, 341:515-518.

- Azeveido, J.R., Torres, O.J.M., Czecko, N.G., Tuon, F.F., Nassif, P.A. & Souza, G.D. 2012. Procalcitonin as a prognostic biomarker of severe sepsis and septic shock. *Rev. Col. Bras. Cir*, 39(6): 456-460.
- Bloos, F., Marshall, J.C. & Dellinger, R.P. 2011. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. *Crit Care* , 15:R88.
- Bossink, A.W., Groeneveld, A.B. & Thijs, L.G. 1999. Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase-alpha1-antitrypsin, and lactoferrin compared with clinical variables. *Clin Infect Dis*, 29:398-407.
- Brunkhorst, F.M., Wegscheider, K., Forycki, Z.F. & Brunkhorst, R. 2000. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. *Intensive Care Med*, 26(2):S148-152.
- Buckley, T.A., Gomersall, C.D. & Ramsay, S.J. 2003. Validation of the multiple organ dysfunction (MOD) score in critically ill medical and surgical patients. *Intensive Care Med*, 29:2216-2222.
- Castelli, G.P., Pognani, C., Meisner, M., Stuardi, A., Bellomi, D. & Sgarbi, L. 2004. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. *Crit Care*, 8:R234-R240.
- Charles, P.E., Dalle, F., Aho, S., Quenot, J.P., Doise, J.M., Aube, H., Olsson, N.O. & Blettery, B. 2006. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. *Intensive Care Med*, 32:1577-1583.
- Charles, P.E., Tinel, C., Barbar, S., Aho, S., Prin, S., Doise, J.M., Olsson, N.O., Blettery, B. & Quenot, J.P. 2009. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome, *Critical Care*, 13:R38 (doi:10.1186/cc7751).
- Charles, P.E., Ladoire, S., Aho, S., Quenot, J.P., Doise, J.M., Prin, S., Olsson, N.O. & Blettery, B. 2008. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either gram negative or gram positive bacteria. *BMC Infect Dis*, 8:38.
- Clec'h, C., Ferriere, F., Karoubi, P., Fosse, J.P., Cupa, M., Hoang, P. & Cohen, Y. 2004. Diagnostic and Prognostic Value of procalcitonin in Patient with Septic Shock. *Crit Care Med*, 32(5):1166-1169.
- Clec'h, C., Ferriere, F., Karoubi, P., Fosse, J.P., Cupa, M., Hoang, P. & Cohen, Y. 2004. Diagnostic and prognostic value of procalcitonin in patients with septic shock. *Crit Care Med*, 32:1166-1169.
- Cook, R., Cook, D., Tilley, J., Lee, K. & Marshall, J. 2001. Multiple organ dysfunction:

- baseline and serial component scores. *Crit Care Med*, 29:2046–2050.
- Dahaba, A.A., Hagara, B., Fall, A., Rehak, P.H., List, W.F. & Metzler, H. 2006. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. *Br J Anaesth*, 97: 503-8.
- Dandona, P., Nix, D., Wilson, M.F., Aljada, A., Love, J., Assicot, M. & Bohuon, C. 1994. Procalcitonin increase after endotoxin injection in normal subjects. *J Clin Endocrinol Metab*, 79:1605-1608.
- Eberhard, O.K., Haubitz, M., Brunkhorst, F.M., Kliem, V., Koch, K.M. & Brunkhorst, R. 1997. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. *Arthritis Rheum*, 40:1250-1256.
- Figueiredo, N., Chora, A., Raquel, H., Pejanovic, N., Pereira, P. & Hartleben, B. 2013. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. *Immunity*, 39(5):874–884.
- Fraunberger, P., Wang, Y. & Holler, E. 2006. Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever. *Shock*, 26:10-2.
- Fujishima, S. & Aikawa, N. 1995. Neutrophil-mediated tissue injury and its modulation. *Intensive Care Med*, 21(3):277–285.
- Fujishima, S., Gando, S., Saitoh, D., Mayumi, T., Kushimoto, S. & Shiraishi, S. A. 2014. Multicenter, prospective evaluation of quality of care and mortality in Japan based on the Surviving Sepsis Campaign guidelines. *J Infect Chemother*, 20(2):115–120.
- Giamarellos-Bourboulis, E.J., Mega, A. & Grecka, P. 2002. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?. *Intensive Care Med*, 28:1351 – 1356.
- Gibot, S., Cravoisy, A., Kolopp-Sarda, M.N., Bene, M.C., Faure, G., Bollaert, P.E. & Levy, B. 2005. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C- reactive protein plasma concentrations during sepsis. *Crit Care Med*, 33:792-796.
- Gotts, J.E. & Matthay, M.A. 2016. Sepsis: pathophysiology and clinical management. *BMJ*, 353:i1585.
- Halim, D., Murni, T. & Redjeki, I. 2009. Comparison of APACHE II, SOFA and modified SOFA scores in intensive care unit at Dr. Hasan Sadikin General Hospital. *Criti Care & Shock*, 12: 157-169.

- Han, Y.Y., Doughty, L.A., Kofos, D., Sasser, H. & Carcillo, J.A. 2003. Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. *Pediatr Crit Care Med*, 4:21-25.
- Harbarth, S., Holeckova, K., Froidevaux, C., Pittet, D., Ricou, B., Grau, G.E., Vadas, L. & Pugin, J. 2001. Diagnostic value of procalcitonin, inter-leukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. *Am J Respir Crit Care Med*, 164:396-402.
- Harbarth, S., Holeckova, K., Froidevaux, C., Pittet, D., Ricou, B. & Grau, G.E. 2001. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. *Am J Respir Crit Care Med*, 164:396-402.
- Hashimoto, S., Kobayashi, A., Kooguchi, K., Kitamura, Y., Onodera, H. & Nakajima, H. 2000. Upregulation of two death pathways of perforin/granzyme and FasL/ Fas in septic acute respiratory distress syndrome. *Am J Respir Crit Care Med*, 1(1):237–243.
- Hatherill, M., Shane, M.T., Turner, C., Ratnavel, N. & Murdoch, I.A. 2000. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. *Crit Care Med*, 28:2591-2594.
- Hausfater, P., Juillien, G., Madonna-Py, B., Haroche, J., Bernard, M. & Riou, B. 2007. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. *Crit Care*, 11: R60.
- Hayashi, T., Nakamura, T. & Takaoka, A. 2011. Pattern recognition receptors. *Jpn J Clin Immunol*, 34:329–45.
- Hazrati, E., Tavakoli, M., Alizadeh, H., Mahdavian, B. & Noorifard, M. 2016. The Correlation between Serum Procalcitonin and Sequential Organ Failure Assessment Score in Severe Sepsis patients, *J. Curr. Res. Sci*, 1:135-139.
- Hegazy, M.A., Omar, A.S., Samir, S., Moharram, A., Weber, S. & Radwan, W.A. 2014. Amalgamation of procalcitonin, C-reactive protein, and sequential organ failure scoring system in predicting sepsis survival. *Anesthesia: Essays and Researches*, 8(3).
- Hermans, M.A., Leffers, P., Jansen, L.M., Keulemans, Y.C. & Stassen, P.M. 2012. The value of the Mortality in Emergency Department Sepsis (MEDS) score, C-reactive protein and lactate in predicting 28-day mortality of sepsis in a Dutch emergency department. *Emerg Med J*, 6:295-300.
- Hoeboer, S.H. & Groeneveld, A.B. 2013. Changes in circulating procalcitonin versus C-reactive protein in predicting evolution of infectious disease in febrile, critically ill patients. *PLoS One*, 8(6):e65564. Tersedia di <https://www.ncbi.nlm.nih.gov/pubmed/23762396> [diakses 14 Agustus 2017].

- Iwashyna, T.J., Ely, E.W., Smith, D.M. & Langa, K.M. 2010. Long-term cognitive impairment and functional disability among survivors of severe sepsis. *JAMA*, 304(16):1787-1794.
- Jensen, J.U., Heslet, L., Jensen, T.H., Espersen, K., Steffensen, P. & Tvede, M. 2006. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. *Crit Care Med*, 34:2596-2602.
- Jensen, J.U., Heslet, L., Jensen, T.H., Espersen, K., Steffensen, P. & Tvede, M. 2006. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. *Crit Care Med*, 34: 2596–602.
- Jeong, A.R., Yang, J.H., Lee, D., Park, C.M., Suh, G.Y., Jeon, K., Cho, J., Baek S.Y., Carriere, K.C. & Chung, C.R. 2015. Clinical Usefulness of Procalcitonin and C-Reactive Protein as Outcome Predictors in Critically Ill Patients with Severe Sepsis and Septic Shock. *PLoS ONE* 10(9): e0138150. Tersedia di <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0138150> [diakses 14 September 2017].
- José, R.A., Torres, J.M.O., Beraldi, R.A., Ribas, C.A.P. & Malafaia, O. 2014. Prognostic evaluation of severe sepsis and septic shock: Procalcitonin clearance vs Δ Sequential Organ Failure Assessment. *Journal of Critical Care*,
- Juneja, D., Singh, O., Nasa, P. & Dang, R. 2012. Comparison of newer scoring systems with the conventional scoring systems in general intensive care population. *Minerva Anesthesiologica*, 78 (2): 194-200.
- Kajdacsy-Balla, A.A.C., Andrade, F.M., Moreno, R., Artigas, A., Cantraine, F., Vincent, J.L. 2005. Use of the sequential organ failure assessment score as a severity score. *Intensive Care Med*, 31:243–249.
- Kibe, S., Adams, K. & Barlow, G. 2011. Diagnostic and prognostic biomarkers of sepsis in critical care. *J Antimi- crob Chemother*. 66(2):ii33-40.
- Knaus, W.A., Draper, E.A., Wagner, D.P. & Zimmerman, J.E. 1983. APACHE II: a severity of disease classification system. *Crit Care Med*, 13:818-29.
- Krüger, S., Ewig, S., Marre, R., Papassotiriou, J., Richter, K. & von Baum, H. 2008. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. *Eur Respir J*, 31:349-55.
- Lemiale, V., Renaud, B., Moutereau, S., NGako, A. & Salloum, M. 2007. A single procalcitonin level does not predict adverse outcomes of women with pyelonephritis. *European Urology*, 51:1394-1401.
- Levy, M.M., Dellinger, R.P., Townsend, S.R., Linde-Zwirble, W.T., Marshall, J.C. & Bion, J. 2010. The Surviving Sepsis Campaign: results of an international guideline- based performance improvement program targeting severe sepsis. *Crit*

Care Med, 38(2):367–74.

Levy, M.M., Macias, W.L. & Vincent, J.L. 2005. Early changes in organ function predict eventual survival in severe sepsis. *Crit Care Med*, 33:2194–2201.

Luo, L., Zhang, S., Wang, Y., Rahman, M., Syk, I. & Zhang, E. 2014. Proinflammatory role of neutrophil extracellular traps in abdominal sepsis. *Am J Physiol Lung Cell Mol Physiol*, 307(7):L586–96.

Luyt, C.E., Guerin, V., Combes, A, Trouillet, J.L., Ayed, S.B., Bernard, M., Gibert, C. & Chastre, J. 2005. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. *Am J Respir Crit Care Med*, 171:48-5.

Martin, G.S., Mannino, D.M., Eaton, S. & Moss, M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. *New Engl J Med*, 348:1546–1554.

Martin, Garry. 2012. Sepsis, severe sepsis, and septic shock: changes in incidence, pathogens and outcomes. *Expert Rev Anti Infect Ther*, 10:701-6.

Meisner, M., Lohs, T., Hüttemann, E., Schmidt, J., Hüller, M. & Reinhart, K. 2001. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. *Eur J Anaesthesiol*, 18:79-87.

Meisner, M., Tschaikowsky, K., Hutzler, A., Schick, C. & Schüttler, J. 1998. Postoperative plasma concentrations of procalcitonin after different types of surgery. *Intensive Care Med*, 24(7):680-684.

Meisner, M., Tschaikowsky, K., Palmaers, T. & Schmidt, J. 1999. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. *Crit Care*, 3(1):45-55.

Meisner, Michael. 1996. *Procalcitonin. A new innovative infection parameter. Biochemical and clinical aspects*. Berlin: Brahms Diagnostica.

Meisner, Michael. 2002. Pathobiochemistry and clinical use of procalcitonin. *Clinica Chimica Acta*, 323(1-2):17–29.

Meisner, Michael. 2010. *Procalcitonin – Biochemistry and Clinical Diagnosis*. Bremen:UNI-MED.

Meisner, Michael. 2013. Current status of procalcitonin in the ICU. *Neth j crit care*, 17(2):4-12.

Meng, L. Su, Y.Q., Tang, Q., Wen, Y.S. & Liu, Z.F. 2009. Serum procalcitonin at the time of admission to the ICU as a predictor of short-term mortality. *Clinical Biochemistry*, 42(10):1025–103.

Merle, C., Lepouse, C.D., Garine, A., Frayssinet, N., Leymarie, F. & Leon, A. 2004.

- Surgery for mesenteric infarction: prognostic factors associated with early death within 72 hours. *Journal of Cardiothoracic and Vascular Anesthesia*, 18(6):734-74.
- Miro, M., del Valle, García, S., Agámez, G., Pimentel, P., Hurtado, M.E. & Olivas, E. 2011. Correlation between SOFA score and procalcitonin blood levels in peritonitis patients, *EJA*, 48 (28): 173.
- Moreno, R., Miranda, D.R., Matos, R. & Fevereiro, T. 2001. Mortality after discharge from intensive care: the impact of organ system failure and nursing workload use at discharge. *Intensive Care Med*, 27:999–1004.
- Nessler, N., Launey, Y., Aninat, C., Morel, F., Malledant, Y. & Seguin, P. 2012. Clinical review: the liver in sepsis. *Crit Care*, 16(5):235.
- Nijsten, M.W., Olinga, T.H., de Vries, E.G., Koops, H.S., Groothuis, G.M., Limburg, P.C., ten Duis, H.J., Moshage, H, Hoekstra, H.J., Bijzet, J.H. & Zwaveling. 2000. Procalcitonin-behaves as a fast responding acute phase protein in vivo and in vitro. *Crit Care Med*, 28(2):458-461.
- Novotny, A., Emmanuel, K. & Matevossian, E. 2007. Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis. *Am J Surg*, 194: 35-9.
- Opitz, B., van Laak, V., Eitel, J. & Suttorp, N. 2010. Innate immune recognition in infectious and noninfectious diseases of the lung. *Am J Respir Crit Care Med*, 181(12):1294-309.
- Pettilä, V., Hynninen, M. & Takkunen, O. 2002. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. *Intensive Care Med*, 28(9):1220 – 1225.
- Pupelis, G., Drozdova, N., Mukans, M. & Malbrain, M. 2014. Serum procalcitonin is a sensitive marker for septic shock and mortality in secondary peritonitis. *Anaesthesiology Intensive Therapy*, 46(4):262–273.
- Rau, B., Steinbach, G. & Gansauge, F. 1997. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. *Gut*, 41(6):832-840.
- Reinhart, K & Meisner, M. 2011. Biomarkers in the critically ill patient: procalcitonin. *Critical Care Clinics*, 27(2):253–263.
- Reinhart, K. & Bloos, F. 2011. *The pathophysiology of sepsis and multiple organ dysfunction*. In: Vincent, J.L., Abraham, E. & Moore, F.A. editors. The textbook of critical care. 6th edition. Philadelphia: Elsevier Saunders.
- Ruiz-Alvarez, M.J., Garcia-Valdecasas, S., De Pablo, R., Sanchez, Garcia, M., Coca, C. & Groeneveld, T.W. 2009. Diagnostic efficacy and prognostic value of serum

- procalcitonin concentration in patients with suspected sepsis. *J Intensive Care Med*, 24(1): 63–71.
- Sakre, Y., Suzana, M., Rui, P.M., Herwig, G., Ranieri, V.M., Michalopoulos, A. & Vincent, J.L. 2012. Patterns and early evolution of organ failure in the intensive care unit and their relation to outcome. *Critical Care*, 16(6):R222(2-9).
- Sands, K.E., Bates, D.W., Lanken, P.N., Graman, P.S., Hibberd, P.L. & Kahn, K.L. 1997. Epidemiology of sepsis syndrome in 8 academic medical centers. *JAMA*, 278:234–240.
- Sarwono, Jonathan. 2006. *Metode Penelitian Kuantitatif dan Kualitatif*. Yogyakarta: Graha Ilmu.
- Schaefer. 2014. Complexity of danger: the diverse nature of damage-associated molecular patterns. *J Biol Chem*, 289(51):35237–35245.
- Schneider, C.P., Yilmaz, Y. & Kleespies, A. 2009. Accuracy of procalcitonin for outcome prediction in unselected postoperative critically ill patients. *Shock*, 31(6):568 – 573.
- Schroder, J., Staubach, K.H., Zabel, P., Stuber, F. & Kremer, B. 1999. Procalcitonin as a marker of severity in septic shock. *Langenbecks Arch Surg*, 384(1):33-38.
- Schuetz, P., Müller, B., Christ-Crain, M., Stolz, D., Tamm, M. & Bouadma. 2017. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev*, 10:CD007498. Tersedia di <https://www.ncbi.nlm.nih.gov/pubmed/29025194> [diakses 12 November 2017].
- Seitaro, Fujishima. 2016. Organ dysfunction as a new standard for defining sepsis. *Fujishima Inflammation and Regeneration*, 36:24:1-6.
- Seligman, R., Meisner, M., Lisboa, T.C., Hertz, F.T., Filippin, T.B. & Fachel, J.M.G. 2006. Decreases in procalcitonin and c-reactive protein are strong predictors of survival in ventilator-associated pneumonia. *Crit Care*, 10(5):R125.
- Sexton, P.M., Christopoulos, G., Christopoulos, A., Nysten, E.S., Snider Jr, R.H. & Becker, K.L. 2008. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. *Crit Care Med*, 36(5):1637-40.
- Sheu, C.C., Gong, M.N., Zhai, R., Chen, F., Bajwa, E.K. & Clardy, P.F. 2010. Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS. *Chest*, 138(3):559–67.
- Sikovic, A., Markota, A., Fluher J. & Rehar D. 2014. Predictor of 30-day Mortality in Medical Patient with Severe Sepsis or Septic Shock. *Signa Vitae*, 9(2): 47-52.
- Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer,

- M., Bellomo, R., Bernard, G.R., Chiche, J.D., Coopersmith, C.M., Hotchkiss, R.S., Levy, M.M., Marshall, J.C., Martin, G.S., Opal, S.M., Rubenfeld, G.D., Van der Poll, T, Vincent, J.T. & Angus, D.C. 2016. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*, 2(8):315.
- Suárez-Santamaría, M., Santolaria, F., Pérez-Ramírez, A., Alemán-Valls, M.R., Martínez-Riera, A., González-Reimers, E., de la Vega, M.J. & Milena, A. 2010. Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. *Eur. Cytokine Netw.*, 21(1):19-26.
- Sugiyono. 2010. *Metode Penelitian Kuantitatif Kualitatif dan R&D*. Bandung: Penerbit CV Alfabeta.
- Sukardi, 2011. *Metodologi Penelitian Pendidikan: Kompetensi dan Praktiknya*. Jakarta: Bumi Aksara.
- Sumadi, Suryabrata. 2012. *Metodologi Penelitian*. Jakarta: PT. Raja Grafindo Persada.
- Tang, B.M., Eslick, G.D., Craig, J.C. & McLean, A.S. 2007. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis. *Lancet Infect Dis*, 7(3):210-217.
- Tavares, E. & Miñano, F.J. 2010. Immunoneutralization of the aminoprocaltitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. *Clin Sci (Lond)*, 119: 519-553.
- Torio, C.M. & Andrews, R.M. 2013. *National in patient hospital costs: the most expensive conditions by payer, 2011*. Statistical Brief #160. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs.
- Tschaikowsky, M., Hedwig-Geissing, G., Braun, G. & Radespiel-Troeger, M. 2011. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. *Journal of Critical Care*, 26(1):54–64.
- Ugarte, H., Silva, E., Mercan, D., De Mendonca, A. & Vincent, J.L. 1999. Procalcitonin used as a marker of infection in the intensive care unit. *Crit Care Med*, 27(3):498-504.
- Uzzan, B., Cohen, R., Nicolas, P., Cucherat, M. & Perret, G.Y. 2006. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. *Crit Care Med*, 34(7):1-8.
- Viallon, A., Guyomarc'h, S. & Marjollet, O. 2008. Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin. *Eur J Emerg Med*, 15(1): 26-33.

- Vincent, J.L. & Nelson, W. 2011. Is worsening multiple organ failure the cause of death in patients with severe sepsis?. *Crit Care Med*, 39(5):1050-1055.
- Vincent, J.L., Angus, D.C. & Artigas, A. 2003. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. *Crit Care Med*, 31(3):834–840.
- Vincent, J.L., de Mendonca, A. & Cantraine, F. 1998. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. *Crit Care Med*, 26(11):1793–1800.
- Vincent, J.L., Moreno, R. & Takala, J. 1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med*, 22(7):707 – 710.
- Vincent, J.L., Sakr, Y., Sprung, C.L., Ranieri, V.M., Reinhardt, K. & Gerlach, H. 2006. Sepsis occurrence in acutely ill patients. *Crit Care Med*, 34(2):344-353.
- Vosylius, S., Sipylaite, J. & Ivaskevicius, J. 2004. Sequential Organ Failure Assessment Score as the Determinant of Outcome for Patients with Severe Sepsis. *Croat Med J*, 45(6):715-720.
- Wacker, C., Prkno, A., Brunkhorst, F.M. & Schlattmann, P. 2013. Procalcitonin as a diagnostic marker for sepsis: A systematic review and meta-analysis. *Lancet Infect Dis*. 13(5):426-35.
- Zarbock, A., Gomez, H. & Kellum, J.A. 2014. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. *Curr Opin Crit Care*, 20(6):588–595.
- Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T. & Junger, W. 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature*, 464(7285):104–107.